| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
92,438 |
83,702 |
$4.07M |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
15,238 |
15,088 |
$1.24M |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
14,521 |
13,236 |
$1.17M |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
13,159 |
13,043 |
$1.12M |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
17,083 |
15,844 |
$1.03M |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
9,126 |
9,035 |
$812K |
| 90460 |
Immunization administration through 18 years of age via any route, first or only component |
66,255 |
28,095 |
$751K |
| 99460 |
|
1,805 |
1,785 |
$152K |
| 99238 |
Hospital discharge day management, 30 minutes or less |
2,112 |
2,066 |
$134K |
| 96110 |
Developmental screening, with scoring and documentation, per standardized instrument |
14,927 |
10,815 |
$132K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
6,591 |
6,107 |
$81K |
| 90461 |
|
19,612 |
16,274 |
$81K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
1,855 |
1,807 |
$53K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
391 |
388 |
$26K |
| J0702 |
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg |
3,263 |
3,112 |
$24K |
| 99395 |
Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years |
237 |
235 |
$21K |
| 54150 |
|
195 |
193 |
$17K |
| G8510 |
Screening for depression is documented as negative, a follow-up plan is not required |
1,155 |
1,149 |
$17K |
| 96160 |
|
7,459 |
7,366 |
$17K |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
4,940 |
4,604 |
$8K |
| 99383 |
|
89 |
89 |
$8K |
| 92587 |
|
1,290 |
1,277 |
$5K |
| 99384 |
|
31 |
31 |
$3K |
| 96380 |
|
92 |
92 |
$2K |
| 96161 |
|
645 |
635 |
$1K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
12 |
12 |
$1K |
| 99462 |
|
16 |
15 |
$667.68 |
| 90671 |
|
2,800 |
2,790 |
$491.85 |
| 90473 |
|
27 |
27 |
$393.01 |
| G8431 |
Screening for depression is documented as being positive and a follow-up plan is documented |
25 |
24 |
$365.95 |
| 90619 |
|
1,829 |
1,820 |
$345.65 |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
17 |
17 |
$141.78 |
| 94760 |
|
154 |
138 |
$51.84 |
| 97803 |
|
3,984 |
3,959 |
$30.31 |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
84 |
83 |
$21.44 |
| 90697 |
|
3,530 |
3,509 |
$8.89 |
| J7613 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg |
17 |
17 |
$1.67 |
| 90677 |
|
849 |
849 |
$1.20 |
| 90686 |
|
5,883 |
5,813 |
$0.45 |
| 90381 |
|
142 |
140 |
$0.39 |
| 90621 |
|
1,359 |
1,338 |
$0.19 |
| 90380 |
|
112 |
109 |
$0.14 |
| 90651 |
|
2,575 |
2,551 |
$0.06 |
| 90672 |
|
503 |
500 |
$0.04 |
| 90715 |
|
1,404 |
1,399 |
$0.04 |
| 90656 |
|
704 |
704 |
$0.03 |
| 90734 |
|
1,025 |
1,016 |
$0.03 |
| 90633 |
|
4,624 |
4,597 |
$0.01 |
| 90710 |
|
2,104 |
2,094 |
$0.01 |
| 90716 |
|
1,850 |
1,841 |
$0.00 |
| 90698 |
|
3,581 |
3,547 |
$0.00 |
| 90680 |
|
6,258 |
6,215 |
$0.00 |
| 90696 |
|
1,747 |
1,741 |
$0.00 |
| 90744 |
|
2,109 |
2,093 |
$0.00 |
| 90723 |
|
28 |
28 |
$0.00 |
| 90688 |
|
13 |
13 |
$0.00 |
| 90648 |
|
1,408 |
1,404 |
$0.00 |
| 90707 |
|
1,806 |
1,798 |
$0.00 |
| 99177 |
|
1,602 |
1,585 |
$0.00 |
| 90700 |
|
1,627 |
1,619 |
$0.00 |
| 90670 |
|
5,706 |
5,666 |
$0.00 |
| 99173 |
|
22 |
21 |
$0.00 |